TB-500

What is TB-500?

TB-500 is a name used in the gray-market peptide trade for a synthetic version of thymosin beta-4 (Tβ4), or for a short fragment of it. Thymosin beta-4 is a 43-amino-acid peptide found inside almost every human cell, and it is especially abundant in platelets and white blood cells.

The name is a historical accident. Tβ4 was first isolated from thymosin fraction 5, a calf thymus extract studied for its immune effects. Researchers later concluded that none of the peptides isolated from that extract were true thymic hormones, and Tβ4 turned out to be a general-purpose cell protein rather than a product of the thymus.²

What is sold as TB-500 is not consistent. Some vendors sell full-length synthetic Tβ4. Others sell a short fragment built around the LKKTETQ actin-binding sequence, sometimes with an acetyl group added. A recent sports medicine review describes TB-500 as a thymosin beta-4 fragment and lists it among the unapproved peptides marketed directly to patients.⁶ A buyer generally cannot tell which molecule is in the vial without independent testing.

TB-500 is promoted mainly for tendon, ligament and muscle injuries, faster recovery from training, and general healing, often stacked with BPC-157. It is not approved for any use, and it is banned in sport. Pharmaceutical development of thymosin beta-4 itself has focused on eye drops and topical gels, not on injectable recovery products.

How TB-500 works

Cells move and change shape by building and dismantling an internal scaffold made of a protein called actin. Thymosin beta-4 holds onto loose actin units and controls when they are released for building. That matters whenever cells need to crawl somewhere, such as skin cells closing a cut or blood vessel cells forming new capillaries. The theory behind TB-500 is that adding more of this peptide helps repair cells reach the injury and get to work.

Platelets show the system clearly. In a resting platelet only a minority of the actin is assembled into filaments, partly because thymosin beta-4 binds the free units. When the platelet is activated, actin assembles rapidly to form the extensions that help plug a wound.⁵

In more precise terms, beta-thymosins are the main intracellular G-actin-sequestering peptides in most vertebrate cells. Tβ4 is unstructured on its own and folds when it binds monomeric actin, with an affinity that allows fast binding and release.² Not all of its reported effects fit a simple monomer-buffering role, and review authors have proposed that it also acts on signaling pathways that shape cell motility.¹ Its N-terminal fragment, acetyl-SDKP, has separately been described as a natural inhibitor of blood cell production in bone marrow.⁷ How extracellular Tβ4, the form delivered by injection, produces its effects is still poorly understood.²

What the research shows on TB-500

The best human evidence is not for TB-500 as sold. It is for pharmaceutical-grade thymosin beta-4 applied to skin and eyes. A review by scientists who helped develop Tβ4 for wound healing reported that it sped repair in phase 2 trials in patients with pressure ulcers, venous stasis ulcers and epidermolysis bullosa wounds, and that it was well tolerated.⁸ These were small trials, the authors were not independent of the program, and the product has not been approved for these wounds.

Animal data are broader. Tβ4 increased the rate of skin healing in several animal models, including diabetic and aged animals, and in burns.⁸ Rodent studies have also explored heart, eye and nerve repair, which is why cardiac research appears among its listed uses. None of that work has produced an approved injectable treatment.

For the musculoskeletal uses that drive demand, the human evidence is close to nil. A 2026 primer for orthopedic and sports medicine physicians concluded that Tβ4 and TB-500 promoted angiogenesis and tissue repair in preclinical models, but that human orthopedic data are lacking.⁴ A separate orthopedic review reached a similar conclusion: the preclinical findings are promising, but clinical trials are missing.³

A 2026 review in Sports Medicine went further. It noted that many unapproved peptides look favorable in animal models, that rigorous human safety data are scarce, and that there is potential for serious harm. It also discussed the placebo effect as a likely contributor to reported benefits, amplified by social media.⁶ That matters because most TB-500 success stories are self-reported, uncontrolled, and involve injuries that often improve on their own.

Studied for: Soft tissue repair research, Wound healing, Cardiac repair research.

TB-500 reference data

TB-500 dosage in published research

Open this in the dosage calculator ↗

How TB-500 is used in practice

Almost all TB-500 reaches users as a freeze-dried powder labeled for research use only. Users mix it with bacteriostatic water and inject it under the skin or into muscle, usually on a loading schedule followed by less frequent maintenance doses. Those schedules come from vendors, forums and some clinics. They are not derived from clinical trials, because no trial has tested injected TB-500 for these purposes.

Some wellness and sports clinics have offered TB-500, sometimes combined with BPC-157. Because it is not approved and compounding pharmacies face restrictions on using it, most supply comes from online sellers operating outside regulatory oversight, which a 2026 review describes as a gray market.⁶

Quality is the practical problem. Independent testing of gray-market peptides has repeatedly found products that are underdosed, mislabeled or contaminated. For TB-500 there is the added confusion between the full-length peptide and the fragment. Sterility and endotoxin testing are rarely documented. Competitive athletes face another issue: thymosin beta-4 and its fragments are prohibited at all times under anti-doping rules.

TB-500 risks and side effects

Reported side effects include injection-site redness or pain, transient fatigue, a brief head rush and mild nausea. These reports are mostly anecdotal. The phase 2 trials of topical Tβ4 found it well tolerated, but that tells us little about repeated systemic injections of products of uncertain identity and purity.⁸

The main theoretical concern is cancer. Tβ4 encourages cell migration and new blood vessel growth, two processes tumors also exploit. No human data show that TB-500 causes or accelerates cancer, but there is also no long-term safety data to rule it out. People with an active or suspected malignancy are generally advised to avoid it.

There is no safety data in pregnancy or breastfeeding, and none in children. Drug interactions have not been studied. Injecting any nonsterile product carries a risk of abscess or infection, and impurities from synthesis can cause immune reactions. Finally, the uncertainty about what is in a given vial means side effects may come from the contents rather than from thymosin beta-4 itself.

Reported side effects

Alternatives to TB-500

For tendon, ligament and muscle injuries, the options with real evidence are less exciting but more reliable. Structured physical therapy with progressive loading is first-line for most tendinopathies. Relative rest, activity modification and short courses of anti-inflammatory drugs help in the acute phase. Corticosteroid injections can give short-term relief in some conditions. Platelet-rich plasma has mixed but growing trial data for specific injuries, and surgery remains appropriate for complete tears. Sports medicine authors recommend discussing these alternatives with patients who ask about peptides.⁶

For chronic wounds, standard care such as debridement, offloading for diabetic foot ulcers and compression for venous ulcers has the strongest evidence. Becaplermin gel is FDA approved for certain diabetic foot ulcers.

BPC-157 and GHK-Cu are often suggested as alternatives, but their evidence for musculoskeletal repair in humans is just as thin.⁴

Questions for a clinician

• What evidence applies to my situation, and at what level?
• What established alternatives should I consider first?
• What monitoring would be necessary, and how often?
• Can this be prescribed at all where I live, or only sold for research?